This set-up is a chartist's dream, and the odds are stacked heavily in favour of a significant rally.
Canopy Growth keeps growing like a weed!
This is one of the members of the hot "pot stocks" in Canada and the US that draws headlines as pot comes in from the cold. The health benefits of cannabis have been known for generations, yet many still cling to the idea that it is a harmful drug and should be banned. Political pressure has kept cannabis in the weeds, as it were. But things are changing as more countries legalise.
I well recall seeing the unintentionally hilarious and clumsy 1936 propaganda film Reefer Madness in the 1970s that melodramatically pictured teenagers being lured by pushers into an over-the-top drug habit. But that was aimed at the recreational use, not the more investor-friendly pharma aspect, which has suddenly arrived on the scene.
Today, the medical benefits of cannabis are increasingly being accepted, but it is no easy matter growing suitable pharma products. In fact, Canopy Growth (TSE:WEED) along with others are still perfecting the cultivation techniques in the face of supply worries. But the potential market is huge.
With the list of cannabis investment products growing (there is even a tradeable Cannabis Index), interest in this sector can only grow – and Canopy Growth is one of the leaders. Here is the all-important chart:
Source: interactive investor Past performance is not a guide to future performance
In fact, this chart is an Elliottician's dream! It shows very clearly a series of five waves up and then three waves down – the very definition in Elliott terms of an impulsive move – in this case, up.
Note the large momentum divergence at the Christmas low at $25 which, importantly, did not break below the former low. At Christmas, markets were falling heavily and production worries for Canopy Growth - along with the other cannabis producers – were intense.
But using the old Buffett maxim: Buy when the others are panic selling, that was a terrific opportunity to get in at a low price.
Since then, the shares have climbed (in another 'five up') and then corrected in a three, and then swiftly reversed to break my blue trendline in late April to confirm the uptrend.
And now the shares are pulling back to attempt a “kiss” on that trendline (currently at around $43) where I expect a renewed push up towards the old high at $52 at least.
But if it declines to the pink warning level at around the $40 area, I would likely amend my stance, but odds definitely favour a continued bull run.
For more information about Tramline Traders, or to take a three-week free trial, go to www.tramlinetraders.com.
John Burford is the author of the definitive text on his trading method, Tramline Trading. He is also a freelance contributor and not a direct employee of interactive investor.
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.
We use a combination of fundamental and technical analysis in forming our view as to the valuation and prospects of an investment. Where relevant we have set out those particular matters we think are important in the above article, but further detail can be found here.
Please note that our article on this investment should not be considered to be a regular publication.
Details of all recommendations issued by ii during the previous 12-month period can be found here.
ii adheres to a strict code of conduct. Contributors may hold shares or have other interests in companies included in these portfolios, which could create a conflict of interests. Contributors intending to write about any financial instruments in which they have an interest are required to disclose such interest to ii and in the article itself. ii will at all times consider whether such interest impairs the objectivity of the recommendation.
In addition, individuals involved in the production of investment articles are subject to a personal account dealing restriction, which prevents them from placing a transaction in the specified instrument(s) for a period before and for five working days after such publication. This is to avoid personal interests conflicting with the interests of the recipients of those investment articles.